Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Rydapt

- PMLiVE

Sobi receives NICE recommendation for Altuvoct in severe haemophilia A

Approximately 7,700 people in England are living with the genetic bleeding disorder

- PMLiVE

Rare diseases: Novartis’ Fabhalta recommended by CHMP for C3 glomerulopathy

Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year

- PMLiVE

Amgen’s Blincyto recommended by NICE for new adult leukaemia indication

Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment

- PMLiVE

NICE recommends pharmaand’s Rubraca for advanced ovarian cancer

An estimated 7,500 new cases of the disease were diagnosed in the UK between 2017 and 2019

- PMLiVE

Novartis to expand cardiovascular pipeline with $3.1bn Anthos acquisition

The deal includes a candidate in phase 3 development to prevent complications of atrial fibrillation

- PMLiVE

Novartis’ Kisqali granted MHRA approval to treat early breast cancer patients

The drug is already approved in the UK to treat advanced cases of the disease

- PMLiVE

NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease

About 15,000 people in England are living with the inherited blood disorder

- PMLiVE

AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi

More than 49,000 people are diagnosed with lung cancer in the UK each year

- PMLiVE

AstraZeneca’s Lynparza recommended by NICE to treat advanced breast cancer

BRCA1 and BRCA2 mutations are responsible for 52% and 32% of hereditary breast cancer cases, respectively

- PMLiVE

Novartis’ investigational spinal muscular atrophy gene therapy shows promise in late-stage study

An estimated one in 10,000 infants globally are affected by the rare neuromuscular disease

- PMLiVE

NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree

Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision

- PMLiVE

NICE recommends Immunocore’s Kimmtrak as first drug for aggressive eye cancer

More than 100 patients are expected to be eligible for the treatment every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links